Increasing number of schools of medicine
providing Kampo education

In order to help create an environment where Kampo education is conducted effectively at all of the 82 schools of medicine in Japan, the key to the establishment of Kampo medicine, we develop and implement systematic programs to support skill building, principally assisting medical students to study Kampo medicine, holding Kampo-themed workshops for trainee physicians at clinical training hospitals, giving various seminars for experienced practitioners and running promotion campaigns on this subject.
As a result, the rate of medical schools offering Kampo education reached 100% in FY2019, and 79 schools have opened outpatient Kampo clinics. Kampo medicine has become part of the standard medical curriculum.

^*Survey by Tsumura

Evidence-based proof
of efficacy

• In order to establish a position for Kampo formulations as a treatment option, it is necessary to prove the efficacy and safety of Kampo formulations in the field of Western medicine. The entire industry has therefore been engaged in basic and clinical research, and in building a substantial body of evidence.
  As a result of successful evidence accumulation, we have more than doubled the number of write-ups in treatment guidelines over the past 10 years.

  • Source：Japan Society for Oriental Medicine EBM Committeehttp://www.jsom.or.jp/medical/ebm/index.html
  • Source：Clinical Practice Guidelines For Kampo Medicine-Containing Products in Japan (KCPG), published by Japan Kampo Medicine Manufacturers Associationhttps://www.nikkankyo.org/serv/serv2.html

• 

• • Source：Japan Society for Oriental Medicine EBM Committee http://www.jsom.or.jp/medical/ebm/index.html
  • Source：Clinical Practice Guidelines For Kampo Medicine-Containing Products in Japan (KCPG), published by Japan Kampo Medicine Manufacturers Association https://www.nikkankyo.org/serv/serv2.htm

Three key areas
of Kampo medicine

We offer Kampo solutions to treatment areas of high degree of medical need related to “geriatric health,” “cancer (supportive care)” and “women’s health,” targeting diseases that are resistant to new Western drugs and challenged by low satisfaction with treatment, and for which prescription Kampo formulations have demonstrated special efficacy.
These areas are expected to draw further attention, due to changes in the structure of disease resulting from a rapidly aging population, a growing number of working women, and other social factors.

Extensive implementation
of e-promotion

From FY2019, we began to strengthen e-promotion to enhance the means of information provision in order to approach medical practitioners in various ways via owned media.
Specific programs range from the streaming of videos and webinars to online Kampo MR activities and interviews with MRs. As a result, in FY2021, the number of times that physicians have recognized information doubled year on year. In FY2022, the number reached 4.77 million.

• Source：Impact Track survey by INTAGE Healthcare Inc.

High barrier to entry
in the prescription
Kampo formulation market

The Tsumura Group’s business is engaged in harnessing the blessings of nature, especially plants, a source of crude drugs, and is characterized by a long supply chain that ranges from the cultivation and procurement of raw material crude drugs to quality management, R&D, manufacturing, and distribution. Our proprietary Kampo value chain built over a long period of time poses a high barrier to entry, giving us an enormous competitive advantage over potential new entrants.
Since crude drugs are natural substances, the component content varies depending on factors such as production area, cultivation environment, and processing and storage conditions.
However, they must achieve clinical reproducibility in order to become pharmaceutical products, and this is ensured by stable quality of crude drugs and the technology and expertise to create consistent Kampo products in the formulation process.

• Groups of products made under the same conditions are referred to as a lot. The smallest unit of information when producing products is referred to as production lot information.

• Trends Related to Prescription Kampo Products
• Domestic Business

Huge potential of the Chinese market

The Healthy China 2030 initiative promoted by the Chinese government places importance on both modern medicine and Chinese medicine. The government is promoting the standardization and scale-up of production of traditional Chinese medicine. The Tsumura Group looks to contribute to the development of the Chinese medicine industry, by using our technologies and expertise to ensure the safety, efficacy, and consistency of medicinal products, which have been honed in the Kampo business. To the above end, we are planning to combine our strengths in quality, technology and experience with the customer base and online medical service platform held by Ping An Insurance (Group) Company of China. Through this, we seek to become a well-reputed Chinese medicine company in the Chinese market.